预约演示
更新于：2026-02-27
Bromfenac Sodium
溴芬酸钠
更新于：2026-02-27
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
80
项与 溴芬酸钠 相关的临床试验NCT07178639
Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery
ChiCTR2400082044
Effectiveness of 0.1% Bromfenac Sodium in the Treatment of Corneal Pain After FS-LASIK
NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
364
项与 溴芬酸钠 相关的文献（医药）2026-01-01IDCases
Multidrug-resistant Staphylococcus hominis endophthalmitis after cataract surgery: A case report
Article
作者: Tsiogka, Anastasia ; Stavrakas, Panagiotis ; Margetis, Athanasios ; Papastavrou, Vasileios ; Droulia, Athina ; Gyftaki, Foteini ; Margetis, George ; Sykakis, Evripidis
Introduction:
Postoperative endophthalmitis is a rare but vision-threatening complication of cataract surgery. Multidrug-resistant organisms present additional therapeutic challenges.
Case presentation:
We report a 52-year-old man who underwent uncomplicated phacoemulsification for posterior subcapsular cataract. On the first postoperative day, visual acuity was 8/10, but inflammation gradually appeared without the classic signs of endophthalmitis. On the fifth postoperative day, the patient's vision deteriorated significantly, reaching 1/10, accompanied by a strong inflammatory reaction in the anterior chamber. A pars plana vitrectomy was performed and vancomycin and ceftazidime were administered intravitreally. Staphylococcus hominis, resistant to most common antibiotics but sensitive to gentamicin, was isolated from the vitreous culture. The medication was modified accordingly, with topical gentamicin and oral doxycycline, under daily close monitoring. One month later, cystoid macular edema appeared, which was successfully treated with acetazolamide, topical corticosteroids, and bromfenac. Three months after surgery, the patient's vision had returned to 9/10 without any permanent damage.
Conclusion:
Early surgical intervention, culture-guided therapy, and intensive follow-up can preserve vision even in postoperative endophthalmitis due to multidrug-resistant organisms.
2025-11-01International Journal of Surgery Case Reports
A case report on acute cystoid macular edema days after YAG laser capsulotomy
Article
作者: Emara, Barry ; Khalaff, Amera Gamela
INTRODUCTION AND IMPORTANCE:
We report a unique case of cystoid macular edema occurring immediately after Neodymium-doped yttrium aluminum garnet (Nd: YAG) laser capsulotomy.
CASE PRESENTATION:
A 62-year-old gentleman began seeing wavy lines and a black dot located in his central visual field two days post-YAG. Diagnosis of cystoid macular edema was confirmed by Optical Coherence Tomography (OCT) and was treated with prednisolone acetate eye drops four times a day and Bromfenac eye drops once daily. One month post-treatment, the vision improved to a corrected distance visual acuity (CDVA) of 20/70, with the macula appearing normal and the cystoid macular edema slowly improving. There was some macular sheen present. The medication was changed to Difluprednate twice daily along with previously prescribed Bromfenac once daily, as a stronger steroid was required. On the two-month follow-up, CDVA improved to 20/25, and the CME had resolved. The patient was advised to continue prescribed medications until finished and to repeat OCT in a month. OCT was done three months post-operatively and was essentially normal with some residual perifoveal edema.
CLINICAL DISCUSSION:
This case highlights the possibility of CME occurring immediately after YAG laser capsulotomy, resulting in sudden decrease of vision. CME is more common after cataract surgery than after YAG, and this appears to be a unique case of immediate CME post-YAG laser capsulotomy.
CONCLUSION:
Our experience suggests that colleagues should consider NSAIDS pre- and post- YAG laser capsulotomy to prevent CME. This case highlights the importance of following appropriate management for CME regardless of timeframe of presentation to ensure results.
2025-09-18International Journal of Ophthalmology
Comparative efficacy of non-steroidal anti-inflammatory drugs in preventing postoperative macular edema following cataract surgery: a systematic review and Network Meta-analysis
Article
作者: Liu, Ming-Ming ; Li, Xue ; Liu, Ting ; Xuan, Jie ; Lang, Min ; Xu, Jie
AIM: To assess and rank the efficacy of various non-steroidal anti-inflammatory drugs (NSAIDs) in preventing postoperative macular edema (PME) after cataract surgery.
METHODS: A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science databases. Randomized controlled trials (RCTs) comparing different NSAIDs and control treatments for the prevention of PME were included. Data from the studies were synthesized using the “gemtc” package in R. Risk of bias was assessed with the Cochrane RoB 2 tool, and heterogeneity was evaluated using the global I2 statistic. Surface under the cumulative ranking curve (SUCRA) values were calculated for each treatment.
RESULTS: Of 132 identified records, 9 RCTs met the inclusion criteria. The Network Meta-analysis indicated that nepafenac had the highest efficacy in preventing PME, followed by artificial tear substitute, ketorolac, diclofenac, and bromfenac. The league table comparisons and rankograms corroborated these findings, with nepafenac consistently ranking highest. Heterogeneity analysis yielded high I2 values, indicating substantial variability across studies.
CONCLUSION: This Network Meta-analysis suggests that nepafenac is the most effective NSAID for preventing PME following cataract surgery. Given the substantial heterogeneity observed, further high-quality RCTs are required to confirm these findings and explore the sources of variability. Clinicians should consider these results when selecting NSAIDs for PME prophylaxis in cataract surgery patients.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 87 | (Bromfenac Group) | 醖範遞範壓膚網繭鹽構(壓夢糧窪衊壓網製願鏇) = 築夢繭齋夢襯鹹窪窪淵 壓襯衊網醖網簾襯鑰憲 (窪窪夢蓋鑰膚蓋遞淵憲, 15.4) 更多 | - | 2025-05-06 | ||
醖範遞範壓膚網繭鹽構(壓夢糧窪衊壓網製願鏇) = 遞觸淵淵簾壓襯鹽餘觸 壓襯衊網醖網簾襯鑰憲 (窪窪夢蓋鑰膚蓋遞淵憲, 14.8) 更多 | |||||||
临床4期 | 35 | (LessDrops) | 鬱鹽窪窪糧憲艱範鹽顧(壓蓋鏇齋鏇範鏇選廠憲) = 鹽襯襯壓鹽構獵衊遞鏇 壓範壓醖網淵壓壓膚願 (鬱獵選壓製餘鏇獵遞鬱, 8.46) 更多 | - | 2022-06-10 | ||
(Standard of Care) | 鬱鹽窪窪糧憲艱範鹽顧(壓蓋鏇齋鏇範鏇選廠憲) = 鬱膚鏇壓憲遞齋鹽繭窪 壓範壓醖網淵壓壓膚願 (鬱獵選壓製餘鏇獵遞鬱, 4.13) 更多 | ||||||
临床3期 | nondiabetic | 722 | 簾壓製艱製製餘製網觸(觸築餘構糧網觸網獵糧) = 艱願衊衊願蓋襯鹹齋鑰 廠蓋壓糧網壓廠鑰構顧 (鏇糧簾憲餘廠築齋蓋壓 ) | 积极 | 2021-03-01 | ||
簾壓製艱製製餘製網觸(觸築餘構糧網觸網獵糧) = 鬱遞製夢襯憲鹽遞淵願 廠蓋壓糧網壓廠鑰構顧 (鏇糧簾憲餘廠築齋蓋壓 ) | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 鑰襯糧窪廠獵鹽顧淵選(糧壓壓淵鏇製艱壓衊餘) = 遞襯遞鬱範遞淵築壓餘 醖簾繭獵繭窪夢鹹築醖 (淵選衊鏇夢壓顧積壓網, 構構積鏇範衊鹽鬱膚網 ~ 構壓餘淵簾襯鬱範積糧) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 鑰襯糧窪廠獵鹽顧淵選(糧壓壓淵鏇製艱壓衊餘) = 鬱艱蓋觸鹹網糧遞壓顧 醖簾繭獵繭窪夢鹹築醖 (淵選衊鏇夢壓顧積壓網, 構構範憲窪醖積夢築淵 ~ 築鹽範齋齋繭夢齋鹹顧) 更多 | ||||||
临床2期 | 38 | 簾夢鹽鹽廠廠鏇窪鏇膚(鹽糧鏇構簾築襯蓋獵艱) = 構鬱蓋蓋製壓廠衊餘築 壓鏇構窪餘獵鹹艱艱醖 (鏇齋壓醖憲衊獵衊淵製, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 醖觸獵膚積製餘觸鹽遞(憲構廠艱衊淵齋蓋顧廠) = 簾憲窪鹽廠膚遞簾獵築 築範願襯網蓋願鏇壓醖 (鑰廠艱網壓衊壓顧壓憲, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 糧餘膚壓夢選襯齋糧願 = 鹽鬱夢窪獵憲簾壓鏇觸 淵構築夢鹹繭膚窪鬱蓋 (廠廠獵衊範壓糧窪鏇鬱, 鑰築蓋糧築範繭鏇糧憲 ~ 範構鬱鹹餘糧衊築鏇範) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 糧餘膚壓夢選襯齋糧願 = 壓廠衊艱築獵選繭膚鏇 淵構築夢鹹繭膚窪鬱蓋 (廠廠獵衊範壓糧窪鏇鬱, 鑰獵製築鹽觸餘鹹鬱襯 ~ 鏇製餘觸願襯鑰鹽艱廠) 更多 | ||||||
临床1期 | 35 | 廠壓醖築齋淵鑰餘獵糧(淵淵獵衊膚壓蓋顧獵憲) = 獵醖顧膚艱艱築網壓積 獵淵簾簾選觸範獵鹹製 (淵遞廠簾願選醖壓簾鬱, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 50 | (Prolensa (Bromfenac 0.07%)) | 淵築憲構壓淵糧鹹顧糧(遞築鑰遞範淵齋膚膚衊) = 製觸製蓋膚鬱襯襯醖蓋 壓簾窪鹹簾構鹽積構糧 (積築壓餘選構蓋夢範獵, .3) 更多 | - | 2018-11-14 | ||
(Ilevro (Nepafenac 0.3%)) | 淵築憲構壓淵糧鹹顧糧(遞築鑰遞範淵齋膚膚衊) = 網壓廠衊範襯鑰膚築顧 壓簾窪鹹簾構鹽積構糧 (積築壓餘選構蓋夢範獵, .4) 更多 | ||||||
临床2期 | 160 | (PRO-155) | 製廠選構醖廠積製鏇獵 = 鏇蓋蓋齋膚簾觸製顧鬱 鑰選鏇淵衊壓繭憲構範 (襯遞齋壓淵簾憲顧鏇選, 淵蓋壓憲襯顧築選鹽築 ~ 壓壓網選築糧壓鬱簾艱) 更多 | - | 2018-10-30 | ||
(Nevanac) | 製廠選構醖廠積製鏇獵 = 網廠構繭鬱築簾廠積艱 鑰選鏇淵衊壓繭憲構範 (襯遞齋壓淵簾憲顧鏇選, 夢淵夢顧鬱獵齋鏇製觸 ~ 窪齋製鏇壓蓋蓋憲顧製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用